South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights to leverage its antibody sequence in the chimeric antigen receptor T cell ...

Potential new treatment option for multiple myeloma patients in Korea. Expanded patient access through competitive pricing. SHANGHAI and NANJING, China and PLEASANTON, Calif., Oct. 29, 2025 ...

A team from GC Cell Corp. reported preclinical data on GL-205, a novel allogeneic anti-CD5 CAR-NK being developed for the treatment of T-cell malignancies. GL-205 was developed using cord ...